China Biologic Products Holdings

Taibang Biologic Group is a Chinese biopharmaceutical company that provides a comprehensive range of plasma-derived products. The company's core business includes the development, manufacture, and sale of plasma-derived products and other biopharmaceutical products.

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

China Biologic Announces Completion of Going Private Transaction

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019.

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript

BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2020 financial...

China Biologic Products to Report Third Quarter 2020 Financial Results

Galapagos

Heron Therapeutics

Illumina

Ionis Pharma

REGENXBIO

Ligand Pharmaceuticals

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript

Avon Products

Carlyle Group

Kinross Gold

ManTech

Vipshop Hlds

Aqua America

These stocks slot into any portfolio and will pack a special punch.

7 Ideal Mid-Cap Stocks for a Diverse Portfolio

ACADIA Pharma

Arrowhead Pharmaceuticals

Natera

Spark Therapeutics

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript

As of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share.

Go-Private Offer For China Biologic Products: It Is Undervalued

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript

BBVA Banco Frances SA Sponsored ADR

Discover

Magna International

AMERCO

According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.

5 Undervalued Stocks Growing Book Value

China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript

China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for China Biologic Products Holdings Stock (CBPO)